FSH AND FSH RECEPTOR MODULATOR COMPOSITIONS AND METHODS FOR INHIBITING OSTEOCLASTIC BONE RESORPTION AND BONE LOSS IN OSTEOPOROSIS

The invention discloses compositions and methods for decreasing osteoclast which are useful for the treatment of a variety of bone loss disorders. 18.-. (canceled)9. A pharmaceutical composition for decreasing osteoclast activity and/or osteoclast differentiation in a subject , comprising:at least one of a follicle stimulating hormone modulator (FSHM) or a follicle stimulating hormone receptor modulator (FSHRM) in an amount effective to reduce bioactivity or bioavailability of follicle stimulating hormone in a subject,at least one second therapeutic agent that treats a bone loss disorder in a subject; anda pharmaceutically acceptable carrier.10. The composition of claim 9 , wherein the at least one follicle stimulating hormone modulators or follicle stimulating hormone receptor modulators are selected from the group consisting of small molecules claim 9 , proteins claim 9 , peptides claim 9 , antibodies claim 9 , nucleic acids claim 9 , and combinations thereof.11. The composition of claim 9 , wherein the at least one follicle stimulating hormone modulators or follicle stimulating hormone receptor modulators are selected from the group consisting of siRNA claim 9 , antibodies claim 9 , and combinations thereof.12. The composition of claim 9 , wherein the follicle stimulating hormone receptor modulator comprises (7-[4-[Bis-(2-carbamoyl-ethyl)-amino]-6-chloro-(1 claim 9 ,3 claim 9 ,5)-triazin-2-ylamino)-4-hydroxy-3-(4-methoxy-phenylazo)-naphthalene]-2-sulfonic acid.13. The composition of claim 9 , wherein the follicle stimulating hormone modulator comprises an aminoalkylamide FSH antagonist.14. The composition of claim 9 , wherein the follicle stimulating hormone receptor modulator comprises a thiazolidinone FSH receptor antagonist.15. The composition of claim 9 , wherein the at least one second therapeutic agent is selected from the group consisting of estrogen claim 9 , estrogen agonists claim 9 , estrogen antagonists claim 9 , estrogen receptor modulators claim 9 , ...

Method for inhibiting osteoclast development

wherein X is chlorine, Y is a methyl group, and R is an alkyl group having a carbon chain length of three carbon atoms. A method of inhibiting osteoclast development and a method for preventing bone erosion in a patient using the compositions of Formula I are disclosed.

Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis

The invention discloses compositions and methods for decreasing osteoclast which are useful for the treatment of a variety of bone loss disorders.

Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis

The invention discloses compositions and methods for decreasing osteoclast which are useful for the treatment of a variety of bone loss disorders.

Regulation of osteoclast formation by inhibition of osteoblastic stem cell factor

The present invention provides an inhibitor of osteoblastic stem cell factor binding and/or activity, for example, an antibody or an antisense oligonucleotide. Also provided are pharmaceutical compositions comprising these inhibitors of osteoblastic stem cell factor binding and/or activity. Further provided is a method of regulating the activity of osteoclasts, comprising the step of: inhibiting the binding and/or activity of osteoblastic stem cell factor.

Regulation of osteoclast formation by inhibition of osteoblastic stem cell factor

The present invention provides an inhibitor of osteoblastic stem cell factor binding and/or activity, for example, an antibody or an antisense oligonucleotide. Also provided are pharmaceutical compositions comprising these inhibitors of osteoblastic stem cell factor binding and/or activity. Further provided is a method of regulating the activity of osteoclasts, comprising the step of: inhibiting the binding and/or activity of osteoblastic stem cell factor.

Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis

Method for inhibiting osteoclast development

This invention provides a composition comprising Formula I, or salt thereof,wherein X is chlorine, Y is a methyl group, and R is an alkyl group having a carbon chain length of three carbon atoms. A method of inhibiting osteoclast development and a method for preventing bone erosion in a patient using the compositions of Formula I are disclosed.

THE MODE OF ACTION OF N-MeDCPA ON TRPC CHANNELS

A method of restoring the balance of osteoclast to osteoblast activity in a patient having rheumatoid arthritis comprising administering to a patient a therapeutically effective amount of the compound N-(3,4-dichlorophenyl)-N-methylpropanamide is provided. A method for treating arthritis-induced bone erosion in a patient comprising administering to a patient a therapeutically effective amount of the compound N-(3,4-dichlorophenyl)-N-methylpropanamide is provided. The compound N-(3,4-dichlorophenyl)-N-methylpropanamide is administered in a pharmaceutically acceptable composition to said patient. A mode of action of N-(3,4-dichlorophenyl)-N-methyl propanamide comprising targeting transient receptor potential channels is provided.

Method for inhibiting osteoclast development

This invention provides a composition comprising Formula I, or salt thereof, wherein X is either chlorine or bromine, Y is either hydrogen or an alkyl group having a carbon chain length from 1 to 5 carbon atoms, and R is an alkyl group having a carbon chain length from 1 to 5 carbon atoms, except that X is not chlorine when Y is hydrogen and R is an ethyl group. A method of preventing bone erosion in a patient and a method of reducing inflammation in a patient using the compositions of Formula I are disclosed.